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Abstract
Metals are a key component of many diagnostic imaging and biotechnology applications, and the 
majority of cancer patients receive a platinum-based drug as part of their treatment. Significant 
effort has been devoted to developing tight binding synthetic chelators to enable effective targeted 
delivery of metal-based conjugates, with most successes involving lanthanides rather than 
transition metals for diagnostic imaging. Chemical conjugation modifies the protein’s properties 
and generates a heterogeneous mixture of products. Chelator attachment is typically done by 
converting the amino group on lysines to an amide, which can impact the stability and solubility of 
the targeting protein and these properties vary among the set of individual conjugate species. Site-
specific attachment is sought to reduce complexity and control stability. Here, the metal 
abstraction peptide (MAP) technology was applied to create the claMP Tag, an inline platform for 
generating site-specific conjugates involving transition metals. The claMP Tag was genetically 
encoded into epidermal growth factor (EGF) and loaded with nickel(II) as a model system to 
demonstrate that the tag within the homogeneous inline conjugate presents sufficient solution 
stability to enable biotechnology applications. The structure and disulfide network of the protein 
and chemical stability of the claMP Tag and EGF components were characterized.
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Coupling of chelators to proteins allows for the generation of conjugates that enable metal-
based imaging or therapeutic applications.1–3 Generally this requires optimization of linker 
chemistry and additional purification steps to obtain the desired product.1,4–6 Even though 
the conjugated entities are much smaller in size than the protein molecule, the impact of 
their addition may not be insignificant. These alterations often affect pharmaceutical 
properties, including solubility, chemical and physical stability, and colloidal behavior of the 
protein.7 The magnitude and type of effect depends on the specific position modified and the 
structural attributes of the protein,8 as well as the properties of the linker and attached 
compound.
The physical stability of proteins depends on the core structure, packing interactions and 
surface composition. The surface properties that develop in the folded state affect solubility 
and colloidal stability, but they also determine solvent access to core structural elements that 
contribute to the overall three-dimensional fold and aggregation propensity of the molecule.9 
As such, the composition of the molecule’s surface significantly impacts its stability, which 
is altered by conjugation. This principle is apparent when comparing homologous proteins 
or mutants having the same three-dimensional fold because each variant can exhibit widely 
different stability profiles depending on their distinct surface properties.10,11 Charged 
residues located on the surface of structured proteins often increase the physical stability by 
protecting against thermal unfolding10,11 or by decreasing aggregation propensity due to 
charge-charge repulsion between protein molecules.12 Conjugation to surface-exposed 
lysine residues is commonly used in formation of bioconjugates, and it alters the surface 
charge and causes large product heterogeneity.13 Even though conjugates are successfully 
formed using this chemical method, altering the surface charge can affect the stability of the 
molecule7,14 and also introduce unexpected complexity, as multiple charge states have been 
observed when modifying a single lysine, depending upon its position in the structure.15 To 
be able to control and/or better characterize stability, conjugation to native or engineered 
cysteine residues and non-natural amino acids has been pursued to increase site 
specificity.16 Modification of native cysteine residues in antibodies has been performed by 
reducing inter-strand disulfide bonds and conjugating at these positions. Heterogeneity is 
decreased greatly compared to lysine-based approaches, but complexity remains and 
physical stability can be adversely affected.8,17,18 Introduction of additional cysteine 
residues permits site-specific attachment, and the THIOMAB approach has demonstrated 
success in identifying suitable positions within antibodies for this purpose.19 Site-specific 
attachment of any type permits detailed analysis of the structure and stability of the protein 
conjugate, allowing for selection of desirable attributes.
The claMP Tag is based on the metal abstraction peptide (MAP) composed of the amino 
acid sequence Asn-Cys-Cys (NCC).20–22 It has been shown to bind Ni(II), forming a single 
specific metal-peptide complex structure having an overall charge of 2- 20 and unusual 
binding and release properties.23 Incorporation of the NCC module into longer peptide 
sequences has been shown to have no discernable effect on complex formation.22 Therefore, 
the claMP Tag can be biosynthetically encoded into a protein to generate a linker-less 
bioconjugate,24 which eliminates the need to chemically link to a chelating moiety. The 
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specific metal abstraction chemistry performed by NCC occurs with a variety of transition 
metal ions.23 The claMP Tag also binds cytotoxic metals, such as Pt and Pd, and 
radioisotopes, such as 99mTc, 64/67Cu, and 60Co (unpublished data); thus, it has the potential 
to serve as a metal-binding agent for use in a variety of imaging and therapeutic 
applications.
Our previous study demonstrated that the claMP Tag can be successfully incorporated at 
different positions within a thiol- and disulfide-containing fusion protein composed of 
thioredoxin and epidermal growth factor (EGF) without any negative effects on the 
expression yield, structure, or function of the tagged protein.24 Herein is presented the 
solution stability of this model system, the Ni(II)-claMP-EGF conjugate and the Ni-claMP 
Tag module in the context of the EGF system, to demonstrate the potential of the claMP Tag 
in serving as an inline metal carrier. The inline Ni-conjugates were stored in aqueous 
solution using two different buffers, and UV-vis absorption spectroscopy, liquid 
chromatography, mass spectrometry, NMR, circular dichroism, and static light scattering 
were used to characterize stability and changes in the conjugate structure over a 24-week 
period.
EXPERIMENTAL METHODS
Protein Expression and Purification
Wild-type and claMP Tag constructs were expressed and purified as previously described.24 
Briefly, the DNA sequence was inserted into the pET-32Xa vector using a pET-32Xa/LIC 
cloning kit (Novagen). The plasmid was transformed into the Origami B (DE3) cell strain 
(Novagen) followed by expression in either Luria Broth or MMTM (for NMR samples). All 
of the samples for NMR analysis were grown on 15N-labeled ammonium chloride (Isotech) 
as the nitrogen source. After expression, a 1 L pellet was resuspended, lysed using a French 
Press, and purified using a Hi-Trap Chelating HP column (GE Healthcare) charged with 
Ni(II). Cleavage with thrombin and Factor Xa (Novagen) were completed to obtain the final 
product. Protein concentration was determined using the Bradford assay, and the samples 
were concentrated to approximately 0.2 mM. EGF and EGF-Ni-claMP were each prepared 
in either 50 mM Tris-Cl, 10 mM NaCl, pH 7.3 or 50 mM potassium phosphate (KPi), 10 
mM NaCl, pH 7.3 and stored at 4 °C.
Absorption Analysis
UV-vis spectroscopy was used to monitor Ni(II) incorporation into the claMP Tag and were 
interpreted as described previously.20 Samples were placed in a 1-cm path length cuvette. 
Spectra were acquired from 200-800 nm using a Cary 100 Bio UV-visible 
spectrophotometer (Varian). Quantitation of the absorbance at 310 nm was used to 
determine the amount of intact Ni(II)-claMP Tag in solution.
Size Exclusion Chromatography (SEC)
Size exclusion chromatography was used to assess the purity of the sample and determine if 
larger molecular weight species formed over time. Analysis was performed using a 4.6×300 
mm Yarra SEC-2000, 3 μm pore size column (Phenomenex). The column was equilibrated 
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in “Buffer A” (20 mM Tris-Cl, 10 mM KCl, pH 7.5 before injection of the sample. A 
constant flow rate of 0.35 mL/min “Buffer A” over 40 minutes was used to elute the protein 
from the column. UV absorption at 220 nm was used to monitor protein elution from the 
column. The area of the peak at 8 minutes was used to quantify the amount of monomer at 
each incubation time point.
Anion Exchange Chromatography (AEC)
AEC was performed using a 4.6×250 mM BioLC ProPac WAX-10 column (Dionex). Before 
sample injection, the column was equilibrated using “Buffer A”. Protein was eluted using a 
linear gradient from 0-100% “Buffer B” (“Buffer A” + 500 mM KCl) over 70 minutes. A 
constant flow rate of 1 mL/min was used, and UV absorption at 220 nm was used to monitor 
protein elution from the column. The area of the main peak at 75 minutes was used to 
estimate the amount of protein present. Fluctuations in peak area of approximately 20% 
were observed for duplicate samples analyzed on the same day. Because large run-to-run 
instrument variation in absorbance was observed, the elution profile was used to establish 
trends and not for absolute quantitation.
1H-15N HSQC NMR
To examine the structural stability of the constructs using 2D NMR, EGF and EGF-Ni-
claMP were prepared in two buffer systems at pH 7.3, 50 mM Tris-Cl or 50 mM KPi, each 
containing 10 mM NaCl and 6% D2O. The samples were concentrated to approximately 0.1 
mM for analysis. 1H-15N Heteronuclear Single Quantum Coherence (HSQC) spectra were 
acquired on a 600 MHz Bruker Avance NMR spectrometer with a triple resonance 
cryoprobe. The spectra for EGF-Ni-claMP were acquired with 120 and 217 scans for the 
samples prepared in Tris-Cl and KPi, respectively, with 2048 points in 1H and 128* 
increments in 15N. The numbers of scans used were selected to account for variations in 
sample concentration and achieve a similar signal to noise ratio of approximately 100:1. All 
spectra were obtained at 25 °C. Spectra were obtained at multiple time intervals to evaluate 
time-dependent changes to protein structure. NMRpipe25 and SPARKY26 were used to 
process the spectra and for data analysis. Comparison of line widths at half height was 
performed to establish the proteins were monomeric and relative peak heights were assessed 
to determine the amount of protein remaining in the sample as a function of time.
Static Light Scattering and Intrinsic Fluorescence
Static light scattering (SLS) and intrinsic fluorescence were collected using a Photon 
Technology International (PTI) QM-40 spectrofluorometer (Birmingham, NJ) equipped with 
a four-position sample holder and a Peltier temperature controller (Quantum Northwest). 
Samples were prepared at a protein concentration of 0.5 mg/mL in 50 mM KPi, 10 mM 
NaCl, pH 7.3 and loaded in 0.2 cm × 1 cm path length quartz cuvettes (Starna Cells). The 
intensity of scattered light at the excitation wavelength of 295 nm was detected by a 
photomultiplier tube at an angle 90° to the light source. Intrinsic fluorescence data was 
acquired simultaneously during the static light scattering experiments using a second 
photomultiplier located 180° to the static light scattering detector and monitoring the 
emission from 310 nm to 390 nm. Emission spectra were collected every 2.5 °C from a 
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temperature range of 5 to 80 °C, with a two-minute equilibration at each temperature. Data 
was collected every 1 nm using a 1 second integration time at each wavelength. 
Fluorescence and scattering from the buffer alone were subtracted from all measurements. 
Two samples were analyzed for each variant.
Circular Dichroism
Circular dichroism (CD) measurements were performed using a Chirascan 
spectropolarimeter (Applied Photophysics, Surrey, UK) equipped with a four-position 
sample holder and a Peltier temperature controller (Quantum Northwest). Samples were 
prepared at a protein concentration of 0.035 mg/mL in 50 mM KPi, 10 mM NaCl, pH 7.3 
and loaded into a 0.1-cm path length quartz cuvette (Starna Cells). Spectra were acquired 
every 2.5 °C from 5 to 80 °C, with a one-minute equilibration at each temperature. An 
averaging time of 0.5 seconds/nm and a bandwidth of 1 nm were used. The molar ellipticity 
at 200 nm was plotted as a function of temperature. CD signals from the buffer alone were 
subtracted from all measurements. Two samples were analyzed for each variant.
RESULTS AND DISCUSSION
Here, claMP-Tagged EGF was used as a model system to analyze the stability of the claMP 
Tag in the context of a protein system and verify that incorporation of the claMP Tag does 
not substantially adversely affect protein stability. The tag rapidly becomes fully occupied in 
the presence of the metal transfer agent, efficiently yielding a highly stable single species in 
solution.20,22,24 Nonetheless, in the event of incomplete loading the metal-occupied claMP-
Tagged protein may be separated easily from any residual unreacted proteins using ion 
exchange chromatography because the correctly formed Ni(II) complex develops a 2− 
charge, differentiating it from the unoccupied form. This approach efficiently generates a 
single, homogeneous conjugate species, permitting the stability of the resulting product to be 
well characterized.
Stability of EGF and Ni-claMP Tag within the Conjugate
The stability of the metal-bound claMP Tag is important to investigate in order to 
successfully implement the tag as an inline conjugate for therapeutic and diagnostic 
purposes. Biologics and conjugates must be stable in solution for 1-2 months to retain 
activity during manufacture and administration and for up to two years if formulated as a 
liquid. Most biologics, however, are stored as frozen and/or dried formulations to best 
preserve their integrity during the required shelf life. Accelerated stability studies of ADCs 
have demonstrated that linking drugs molecules to antibodies leads to formation of high 
molecular weight species (HMWS) and diminished structural stability.8,17 In this system 
dimers or HMWS have the potential to result from either covalent crosslinking via disulfide 
bond formation or Ni-based oxidation or bridging via the metal upon liberation from the tag. 
SEC was used to investigate formation of multimers over time. In the initial chromatogram, 
EGF-Ni-claMP elutes as a fully monomeric species exhibited by one main peak at 7.5 
minutes (Figure 1). This is in contrast to native EGF under the same low salt condition, 
which displays an unusual profile consisting of two peaks eluting at approximately 8.5 and 
9.5 minutes. The presence of the two peaks is dependent on buffer concentration, such that 
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analysis of EGF on the SEC column at slightly higher buffer concentration (30 mM Tris, 15 
mM KCl) yields a broad single peak at 9.0 min (data not shown). The expected explanation 
would be that dimerization of native EGF is favored at low ionic strength and that addition 
of the tag inhibits dimer formation. Analysis of the line widths of the NMR data for both 
proteins, however, indicates only monomer is present in each sample (data not shown). 
Because increased ionic strength eliminates the double peak and the protein recovered from 
the column is uniformly monomeric, these peaks likely represent two exchangeable 
conformers. The presence of only one peak in the claMP-Tagged EGF chromatogram 
suggests the protein’s structural flexibility may be restricted to a single conformation in the 
presence of the negatively charged tag, which is adjacent to a patch of basic residues.24 At 
the 12-week time point, the EGF-Ni-claMP peak shape is slightly altered, gaining a shoulder 
peak centered at 8.4 minutes, corresponding to a smaller molecular weight species or the 
emergence of a second conformer, as observed with EGF. These SEC data show no 
evidence of dimers or HMWS even at 24 weeks. Earlier eluting species indicative of protein 
crosslinking or aggregation are not present, implying the global conformation and the Cys 
residues within EGF-Ni-claMP are unaltered. The presence of Ni(II) has been observed to 
cause oxidative crosslinking of proteins.27 As such, the SEC data further implies that nickel 
is not released readily from the claMP Tag because dimers and HMWS do not emerge.
To investigate changes in the Ni-claMP complex, such as loss of metal or alteration of the 
ligands around the metal center, absorption spectroscopy and charge-based separation was 
used. The nickel(II) complex was used to perform this initial stability study because its 
absorption spectrum is rich in structural detail,22 and any chemical or structural 
transformation of the Ni-claMP complex would alter the features in the UV-vis spectrum 
and the unique 2− charge of the complex. The UV-vis absorption data shows that EGF-Ni-
claMP is stable over a 12-week period, as no decreases in peak height were observed for the 
protein and Ni-claMP features (Figure 2). After 24 weeks, a decrease in intensity of the 
feature at 310 nm, which corresponds to the ligand-metal charge transfer band from the Ni-
claMP complex, is observed. Because correct formation of the claMP complex introduces a 
change in charge of 2−, Ni-claMP-Tagged EGF exhibits a significantly different elution 
profile than EGF when separated on an anion exchange column. AEC was used to cross-
validate the stability of Ni-claMP by evaluating the elution profile of soluble claMP-Tagged 
EGF over time. EGF elutes at approximately 35 minutes, whereas EGF-Ni-claMP elutes at 
75 minutes. Samples prepared in either 50 mM Tris-Cl, pH 7.3 or 50 mM KPi, pH 7.3, each 
containing 10 mM NaCl, exhibited the same chromatographic feature at the initial time 
point, confirming the conjugate has the same surface charge regardless of the buffer system 
in which it is prepared (Figure 3). This supports the SEC data, confirming the buffer choice 
does not noticeably impact the behavior of the molecule.
Like native EGF, the AEC peak area of EGF-Ni-claMP prepared in either buffer is constant 
through eight weeks within instrument variability (+/− 20%), indicating the protein remains 
intact and soluble. Peak area for these preparations decreased below the variability threshold 
to approximately 25% and 35% at the 12-week time point for samples prepared in Tris-Cl 
and KPi, respectively (Figure 3). Multiple replicates were analyzed, and peak areas acquired 
from the same sample and different batches were observed to deviate substantially at the 
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same time point. A 15-35% decrease in peak area was observed at the 12-week time point 
depending on the sample analyzed. Because the AEC peak area values were extremely 
variable, this data was not useful for absolute quantitation and instead was used solely in a 
qualitative manner to identify general trends and changes in the profile. EGF-Ni-claMP 
prepared in KPi exhibits a downward trend in peak area starting at the 12-week time point, 
while the sample prepared in Tris-Cl also decreases in peak area, although to a lesser extent. 
The AEC analysis shows that Ni(II) is retained by the claMP complex but also indicates that 
after longer periods of time a change in charge occurs. There is the emergence of an 
additional peak around 50 minutes in the AEC chromatogram of the sample prepared in KPi 
at the 12-week time point, and this feature grows in intensity at later time points. Because 
earlier elution indicates a specie is less negatively charged than the conjugate, this data 
suggests a cleavage event, likely resulting in removal of the Ni-claMP complex, and/or 
alterations in the protein structure near this region has occurred.
Identification of Cleavage Fragment
To further investigate the possible cleavage event and determine if it leads to removal of the 
Ni-claMP complex from EGF, mass spectrometry (MS) was performed. MS analysis of the 
sample after 24 weeks reveals hydrolysis of the peptide backbone occurs following L52 and 
preceding R53, the C-terminal residue of the native EGF sequence. This validates the SEC 
data, which shows emergence of a smaller molecular weight species. It also aligns with the 
AEC results, which indicate the degradant is less negatively charged than the conjugate but 
more negative than native EGF. EGF without its terminal Arg and the Ni-claMP complex 
would exhibit a charge of 5−, causing it to elute later than native EGF but earlier than EGF-
Ni-claMP. The MS data support hydrolytic cleavage of the peptide backbone. Because of 
the large variability observed between different sample preparations in the rate at which this 
species emerges and that cleavage occurs between Leu52 and Arg53, we hypothesize the 
primary degradant observed is caused by a minor, undetectable protease contaminant. 
Because in our previous short-term studies no evidence of proteolysis had been observed, 
the same purification approach was used. To better protect against proteolytic 
contamination, additional purification steps and protease inhibitors could be added to 
optimize the purification, as would be done when generating a therapeutic product. Both 
chymotrypsin and pepsin have been shown to cleave on the C-terminal side of leucine,28 
which is consistent with the location of cleavage in this EGF conjugate. Evidence of metal-
induced hydrolysis has been reported to occur in the presence of various ions, including 
Ni(II).29 This is specific to the sequence SHHK and depends on the presence of one of two 
embedded His. Complete cleavage occurs in a substantially shorter time frame, suggesting 
that it is not the same mechanism. Because the Ni(II)-claMP Tag system undergoes a long 
lag period before degradation begins, it is likely that the eventual release of a small amount 
of Ni(II) activates a proteolytic contaminant. Even in this sub-optimized liquid sample, 
cleavage is minimal up to two months. For research applications, this provides sufficient 
time to carry out most analyses, and for example, if 57Ni is inserted for use in medical 
imaging,30,31 the radioisotope would be inserted into the tag in the nuclear pharmacy, and 
the image would be acquired long before cleavage would occur in the formulation. In 
addition, it is clear that despite the presence of molecular oxygen in the samples throughout 
the incubation, no evidence of oxidation (e.g. methionine sulfoxide) was detected in the MS 
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data, indicating the presence of the Ni-claMP Tag complex does not lead to chemical 
incorporation of oxygen into the targeting protein even after 24 weeks.
The emergence of the cleaved fragment is accompanied by a small amount of visible 
precipitation. The absorption at 280 nm remains constant at 24 weeks, but the absorption of 
the Ni-claMP feature at 310 nm decreases, suggesting selective precipitation of the Arg53-
Ni-claMP fragment. Analysis of the NMR peak intensities also confirms precipitation of 
neither EGF nor EGF-Ni-claMP occurs. It was determined previously that the cysteine 
residues are unaltered by addition of the tag, and as such, these resonances can be used to 
quantify the total amount of soluble monomeric protein in the sample. The peak heights of 
the cysteine residues in the HSQC spectra remain constant over the 24-week period, 
confirming the intact EGF-Ni-claMP and cleaved EGF components remain in solution. The 
peak heights corresponding to Arg53 and the added Gly from the claMP Tag decrease in 
intensity over the 24-week time period, further indicating precipitation of the cleaved 
Arg53-Ni-claMP Tag fragment occurs (Figure 4). Because the net charge of the Arg53-Ni-
claMP fragment is 1−, presuming no other alterations, its aqueous solubility may be limited, 
particularly in the presence of the highly soluble, negatively charged protein, as might be 
predicted based on general principles and other peptides.11
The likelihood of this cleavage event occurring with a claMP-Tagged bioconjugate can be 
reduced by various standard measures, including frozen storage, lyophilization, and 
improving purification procedures to better eliminate proteolytic contaminants derived from 
the host, in this case E. coli. In this study, a simple two-step purification was used, and no 
additional precautions were taken to inhibit proteases, chelate residual or released metal, or 
eliminate oxygen and light exposure during storage. Follow-up studies to examine each 
parameter individually are being pursued to characterize in greater detail their influence on 
conjugate stability. In the construct examined here, a glycine spacer was included between 
EGF and the tag. Examination of a matrix of synthetic peptides and tagged protein variants 
has shown the spacer is unnecessary for metal complex formation (unpublished data), 
indicating the spacer may be removed or substituted. As such, if a spacer is desired, residues 
less prone to rapid cleavage than Gly can be utilized to reduce potential proteolysis. Based 
on this initial study, which demonstrates very good stability of the complex, optimization of 
these external factors will allow for the formation of highly stable claMP-Tagged 
bioconjugates. The basal conditions analyzed provide a good starting point for identifying 
stable formulation conditions, which is an important consideration in the development of 
bioconjugates utilizing the claMP Tag technology.
Impact of the claMP Tag on the Structural Stability of EGF
Because SEC showed the EGF proteins remained entirely monomeric and soluble at 24 
weeks, 2D heteronuclear NMR was used to more closely investigate the local structural 
stability of claMP-Tagged EGF. The 15N-1H HSQC NMR experiment is the most accurate 
tool that can be applied to analyze protein structure in solution because it is a highly 
sensitive reporter of the entire backbone conformation.32–34 It has previously been shown 
that addition of the thiol-containing sequence to the C-terminus of EGF does not negatively 
impact native disulfide bond formation or the higher order structure of the molecule.24 Here, 
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the initial 1H-15N HSQC spectra of EGF-Ni-claMP prepared in each buffer are nearly 
identical, confirming the tertiary structure of EGF-Ni-claMP is not altered by buffer 
selection (Figure 5), consistent with SEC and AEC results. At the 12-week time point, 
additional peaks emerge near the initial resonance positions corresponding to the backbone 
amides from C-terminal residues W49, W50, E51, and L52. The indole NH from the side 
chains of W49 and W50 begin to split from one overlapped peak into two. One of these sets 
of peaks must correspond to the two Trp within the cleaved EGF product. Because of the 
intensity of these NMR peaks and because the MS data shows only two masses, the other 
NMR peaks must represent a slightly altered conformational state. This second set of peaks 
may reflect the cleaved product rather than the full-length species because a peak 
corresponding to the position of L52 in EGF appears and an additional peak in close 
proximity to it also emerges, suggesting a very small conformational adjustment. These 
limited site-specific changes become more distinct at the 24-week time point, yet the global 
structure and disulfide network of the protein remain the same (Figure 6). Based on the 
NMR data, it is clear that there are no significant tertiary structure alterations to the protein 
over time, with the exception of the C-terminal cleavage event confirmed by MS.
Altering the surface properties of the molecule through claMP Tag addition did not 
significantly affect the structure or stability of EGF. Although EGF is a model system and it 
has little regular structure, thermal titration of EGF and EGF-Ni-claMP were performed to 
verify that adding the tag did not alter appreciably the unfolding and aggregation behavior of 
the parent protein. The unusual fold of EGF produces a CD spectrum with atypical features. 
The CD features of Ni-claMP overlap extensively with EGF above 220 nm and are opposite 
in sign, leading to the absence of an informative signal in this portion of the spectrum (Supp. 
Fig. 1a). As such, unfolding of EGF was monitored at 200 nm to detect changes in random 
coil. With and without the tag, EGF behaved identically (Supp. Fig. 1b). The onset 
temperature for unfolding (Tm,onset) is indicative of the physical instability of the conjugate, 
as reported for ADCs.8 As such, the fact that the Tm,onset values of claMP-Tagged EGF and 
native EGF are indistinguishable, indicates that incorporation of the claMP Tag is 
innocuous. Intrinsic Trp fluorescence also was monitored as a function of temperature (data 
not shown). EGF has two Trp residues, both located near the C-terminus. Despite the 
obvious chemical shift change to these residues detected by NMR, no difference in 
fluorescence was observed between the two proteins, suggesting only a minor adjustment to 
the conformation or dynamic properties occurs. Visible precipitation was not observed and 
unfolding was reversible for both species. SLS was used to monitor formation of aggregates 
as a function of temperature, but no scattering could be detected for either protein up to the 
maximum temperature of 80 °C. Because native EGF is highly negatively charged, it is not 
unexpected that making it more negative by addition of the Ni-claMP complex does not 
diminish stability. Charge repulsion and retention of the disulfide bonds likely protects EGF 
from both non-native and colloidal aggregation. In the context of this system, alterations in 
surface charge due to claMP Tag addition were shown to have minimal effects on protein 
stability, which is promising for application of this tag in biotechnology applications. Of 
course, each system to which the claMP Tag is applied would need to be investigated to 
characterize the impact on that specific molecule. Additional studies are ongoing to evaluate 
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the effects on stability of incorporating the claMP Tag into a diverse set of proteins that vary 
in isoelectric point, size, charge, and architecture.
CONCLUSION
In this study, the Ni(II)-claMP Tag complex was shown to retain metal binding and not 
negatively alter the higher order structural stability of the protein molecule to which it is 
attached. Although cleavage of the Arg53-Ni-claMP fragment occurs, there is a two-month 
lag before onset, suggesting degradation can be mitigated by increasing sample and/or 
reagent purity as well as storing it frozen and/or dried. Therefore, this stability analysis of 
the EGF-Ni-claMP conjugate confirms that the claMP Tag module is structurally and 
chemically stable and does not adversely impact the physicochemical stability of the protein 
to which it is attached, here EGF.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
ACKNOWLEDGEMENTS
Funding was provided by Wallace H. Coulter Foundation (CTRA) and KU Cancer Center Pilot Award. NIGMS 
Biotechnology Predoctoral Training Grant (T32 GM-08359) provided support for B.J.M. The authors thank Drs. 
C.R. Middaugh, D. Volkin, and O. Kumru for use of equipment and assistance with CD, SLS, and fluorescence data 
collection and the KU Mass Spectrometry lab for analyzing the mass spectrometry samples.
REFERENCES
1. De León-Rodríguez LM, Kovacs Z. The Synthesis and Chelation Chemistry of DOTA-Peptide 
Conjugates. Bioconjugate Chem. 2008; 19(2):391–402.
2. Breeman WAP, Kwekkeboom DJ, de Blois E, de Jong M, Visser TJ, Krenning EP. Radiolabelled 
regulatory peptides for imaging and therapy. Anti-Cancer Agents Med Chem. 2007; 7(3):345–357.
3. Wängler C, Buchmann I, Eisenhut M, Haberkorn U, Mier W. Radiolabeled peptides and proteins in 
cancer therapy. Protein Pept Lett. 2007; 14(3):273–279. [PubMed: 17346233] 
4. Knör S, Modlinger A, Poethko T, Schottelius M, Wester H-J, Kessler H. Synthesis of novel 
1,4,7,10-tetraazacyclodecane-1,4,7,10-tetraacetic acid (DOTA) derivatives for chemoselective 
attachment to unprotected polyfunctionalized compounds. Chem - Eur J. 2007; 13(21):6082–6090. 
S6082/6081-S6082/6020. [PubMed: 17503419] 
5. Lewis MR, Kao JY, Anderson A-LJ, Shively JE, Raubitschek A. An improved method for 
conjugating monoclonal antibodies with N-Hydroxysulfosuccinimidyl DOTA. Bioconjugate Chem. 
2001; 12(2):320–324.
6. Lewis MR, Raubitschek A, Shively JE. A Facile, Water-Soluble Method for Modification of 
Proteins with DOTA. Use of Elevated Temperature and Optimized pH To Achieve High Specific 
Activity and High Chelate Stability in Radiolabeled Immunoconjugates. Bioconjugate Chem. 1994; 
5(6):565–576.
7. Wakankar AA, Feeney MB, Rivera J, Chen Y, Kim M, Sharma VK, Wang YJ. Physicochemical 
Stability of the Antibody-Drug Conjugate Trastuzumab-DM1: Changes due to Modification and 
Conjugation Processes. Bioconjugate Chem. 2010; 21(9):1588–1595.
8. Beckley NS, Lazzareschi KP, Chih H-W, Sharma VK, Flores HL. Investigation into Temperature-
Induced Aggregation of an Antibody Drug Conjugate. Bioconjugate Chem. 2013; 24(10):1674–
1683.
Mills and Laurence Page 10






















9. Laurence, JS.; Middaugh, CR. Fundamental structures and behaviors of proteins. In: Wang, W.; 
Roberts, CJ., editors. Aggregation of Therapeutic Proteins. Hoboken, NJ: John Wiley & Sons, Inc; 
2010. p. 1-61.
10. Dominy BN, Minoux H, Brooks CL III. An electrostatic basis for the stability of thermophilic 
proteins. Proteins: Struct, Funct, Bioinf. 2004; 57(1):128–141.
11. Glyakina AV, Garbuzynskiy SO, Lobanov MY, Galzitskaya OV. Different packing of external 
residues can explain differences in the thermostability of proteins from thermophilic and 
mesophilic organisms. Bioinformatics. 2007; 23(17):2231–2238. [PubMed: 17599925] 
12. Narhi LO, Arakawa T, Aoki K, Wen J, Elliott S, Boone T, Cheetham J. Asn to Lys mutations at 
three sites which are N-glycosylated in the mammalian protein decrease the aggregation of 
Escherichia coli-derived erythropoietin. Protein Eng. 2001; 14(2):135–140. [PubMed: 11297671] 
13. Wang L, Amphlett G, Blättler WA, Lambert JM, Zhang W. Structural characterization of the 
maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. 
Protein Sci. 2005; 14(9):2436–2446. [PubMed: 16081651] 
14. Acchione M, Kwon H, Jochheim CM, Atkins WM. Impact of linker and conjugation chemistry on 
antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugates. 
MAbs. 2012; 4(3):362–372. [PubMed: 22531451] 
15. Boylan NJ, Zhou W, Proos RJ, Tolbert TJ, Wolfe JL, Laurence JS. Conjugation Site Heterogeneity 
Causes Variable Electrostatic Properties in Fc Conjugates. Bioconjugate Chem. 2013; 24(6):1008–
1016.
16. Strop P, Liu S-H, Dorywalska M, Delaria K, Dushin RG, Tran T-T, Ho W-H, Farias S, Galindo 
Casas M, Abdiche Y, Zhou D, Chandrasekaran R, Samain C, Loo C, Rossi A, Rickert M, Krimm 
S, Wong T, Michael Chin S, Yu J, Dilley J, Chaparro-Riggers J, Filzen GF, O'Donnell CJ, Wang 
F, Myers JS, Pons J, Shelton DL, Rajpal A. Location Matters: Site of Conjugation Modulates 
Stability and Pharmacokinetics of Antibody Drug Conjugates. Chem Biol (Oxford, U K). 2013; 
20(2):161–167.
17. Adem YT, Schwarz KA, Duenas E, Patapoff TW, Galush WJ, Esue O. Auristatin Antibody Drug 
Conjugate Physical Instability and the Role of Drug Payload. Bioconjugate Chem. 2014; 25(4):
656–664.
18. Jackson D, Atkinson J, Guevara CI, Zhang C, Kery V, Moon S-J, Virata C, Yang P, Lowe C, 
Pinkstaff J, Cho H, Knudsen N, Manibusan A, Tian F, Sun Y, Lu Y, Sellers A, Jia X-C, Joseph I, 
Anand B, Morrison K, Pereira DS, Stover D. In vitro and in vivo evaluation of cysteine and site 
specific conjugated herceptin antibody-drug conjugates. PLoS One. 2014; 9(1) e83865/83861-
e83865/83814, 83814 pp. 
19. Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, 
Dennis MS, Lu Y, Meng YG, Ng C, Yang J, Lee CC, Duenas E, Gorrell J, Katta V, Kim A, 
McDorman K, Flagella K, Venook R, Ross S, Spencer SD, Wong WL, Lowman HB, Vandlen R, 
Sliwkowski MX, Scheller RH, Polakis P, Mallet W. Site-specific conjugation of a cytotoxic drug 
to an antibody improves the therapeutic index. Nat Biotechnol. 2008; 26(8):925–932. [PubMed: 
18641636] 
20. Krause ME, Glass AM, Jackson TA, Laurence JS. Novel Tripeptide Model of Nickel Superoxide 
Dismutase. Inorg Chem. 2010; 49(2):362–364. [PubMed: 20000358] 
21. Krause ME, Glass AM, Jackson TA, Laurence JS. MAPping the Chiral Inversion and Structural 
Transformation of a Metal-Tripeptide Complex Having Ni-Superoxide Dismutase Activity. Inorg 
Chem. 2011; 50(6):2479–2487. [PubMed: 21280586] 
22. Krause ME, Glass AM, Jackson TA, Laurence JS. Embedding the Ni-SOD Mimetic Ni-NCC 
within a Polypeptide Sequence Alters the Specificity of the Reaction Pathway. Inorg Chem. 2013; 
52(1):77–83. [PubMed: 23214928] 
23. Laurence, JAS.; Vartia, AA.; Krause, ME. Metal abstraction peptide (MAP) tag and associated 
methods. U.S. Patent. 8,110,402. 2012 Feb 7. 
24. Mills BJ, Mu Q, Krause ME, Laurence JS. claMP Tag: A versatile inline metal-binding platform 
based on the metal abstraction peptide. Bioconjugate Chem. 2014; 25(6):1103–1111.
Mills and Laurence Page 11






















25. Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A. NMRPipe: a multidimensional 
spectral processing system based on UNIX pipes. J Biomol NMR. 1995; 6(3):277–293. [PubMed: 
8520220] 
26. Goddard, TD.; Kneller, DG. SPARKY. San Francisco: University of California; 2004. 
27. Gill G, Richter-Rusli AA, Ghosh M, Burrows CJ, Rokita SE. Nickel-dependent oxidative cross-
linking of a protein. Chem Res Toxicol. 1997; 10(3):302–309. [PubMed: 9084910] 
28. Keil, B. Specificity of Proteolysis. Berlin; New York: Springer-Verlag; 1992. 
29. Bal W, Liang R, Lukszo J, Lee S-H, Dizdaroglu M, Kasprzak KS. Ni(II) Specifically Cleaves the 
C-Terminal Tail of the Major Variant of Histone H2A and Forms an Oxidative Damage-Mediating 
Complex with the Cleaved-Off Octapeptide. Chem Res Toxicol. 2000; 13(7):616–624. [PubMed: 
10898594] 
30. Nielsen GD, Andersen O, Jensen M. Toxicokinetics of nickel in mice studied with the γ-emitting 
isotope nickel-57. Fundam Appl Toxicol. 1993; 21(2):236–243. [PubMed: 8405787] 
31. Zweit J, Carnochan P, Goodall R, Ott R. Nickel-57-doxorubicin, a potential radiotracer for 
pharmacokinetic studies using PET: production and radiolabelling. J Nucl Biol Med. 1994; 38(4 
Suppl 1):18–21. [PubMed: 7632762] 
32. Krause ME, Martin TT, Laurence JS. Mapping Site-Specific Changes That Affect Stability of the 
N-Terminal Domain of Calmodulin. Mol Pharmaceutics. 2012; 9(4):734–743.
33. Skinner AL, Laurence JS. High-field solution NMR spectroscopy as a tool for assessing protein 
interactions with small molecule ligands. J Pharm Sci. 2008; 97(11):4670–4695. [PubMed: 
18351634] 
34. Skinner AL, Laurence JS. Probing residue-specific interactions in the stabilization of proteins 
using high-resolution NMR: a study of disulfide bond compensation. J Pharm Sci. 2010; 99(6):
2643–2654. [PubMed: 20187138] 
Mills and Laurence Page 12























Size exclusion chromatography assessment of the monomeric content of EGF-Ni-claMP 
prepared in either Tris-Cl (a) or KPi (b). At the initial time point, only one species is present 
in both samples. After three months, mostly monomeric protein remains with the emergence 
of a shoulder on the backside of the peak suggests the formation of a smaller molecular 
weight species.
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UV-vis spectroscopy confirms Ni(II) is incorporated into the claMP Tag in both Tris-Cl (a) 
and KPi (b). Ni(II) remains incorporated in the claMP Tag regardless of buffer system 
chosen, as the intensity of the feature at 310 nm remains constant over the 12-week period 
with Tris-Cl (c) and KPi (d). At the 24-week time point, the intensity of the feature at 310 
nm decreases, suggesting alterations occur in the Ni-claMP complex. The intensity of the 
feature at 280 nm remains constant, indicating the protein concentration remains the same 
over the time period investigated.
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Trend analysis by anion exchange chromatography to assess retention of intact EGF-Ni-
claMP. The initial chromatograms of the conjugate prepared in either Tris-Cl (a) or KPi (b) 
are very similar, indicating the buffer choice does not alter formation of conjugate. In the 
sample prepared in KPi buffer, a peak emerges at 50 minutes, indicating formation of a 
species with a less negative charge. c) The area of the peak at 74 minutes was plotted to 
reflect the amount of intact EGF-Ni-claMP remaining. At 12 weeks, the area of this peak 
decreases by 25% and 35% for the samples prepared in Tris-Cl and KPi, respectively. At 24 
weeks, the area of this peak in samples prepared in Tris-Cl and KPi decreases by 
approximately 40% and 70%, respectively. d) The area of the peak at 35 minutes was plotted 
to reflect the amount of intact EGF in solution, and it remains constant over the 24-week 
time period. 20% variability was observed for both EGF and EGF-Ni-claMP.
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Plot of NMR peak heights. The peak height corresponding to Cys residues confirms the 
protein structure is maintained and no loss of protein from solution occurs. The peak heights 
corresponding to the Gly from the claMP tag and C-terminal residues from EGF (L52, R53) 
decrease, indicating a change in structure in this region.
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1H-15N HSQC spectra confirm that buffer selection has no effect on the structure of EGF-
Ni-claMP, as the peaks of the samples prepared in Tris-Cl (blue) and KPi (red) overlap 
completely.
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1H-15N HSQC spectra of EGF-Ni-claMP at T=0 (red), T=12 weeks (blue), and T=24 weeks 
(green). The tertiary structure of the protein is maintained, but specific differences are 
observed in peaks corresponding to the C-terminal region (boxed).
Mills and Laurence Page 18
J Pharm Sci. Author manuscript; available in PMC 2016 February 01.
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
